Ascletis Pharma Inc. (ASCLF)
NEGATIVEFundamental
27
Preço
$9.88
Capitalização de Mercado
$10.11B
Parte 1 · Quanto vale a empresa
Visão Geral
Ascletis Pharma is a Hangzhou-based Chinese biotech that develops and, on a small scale, sells drugs. It already markets treatments for hepatitis C, including Ganovo and a ritonavir tablet, in China, but that legacy business generates only minimal revenue. The company has pivoted most of its research toward metabolic disease — obesity and fatty liver — with pipeline candidates like ASC30 and ASC41, and it has also licensed in a China-market NASH drug, denifanstat, from a US partner.
Como gera receita
Ascletis earns a small amount of revenue selling its approved hepatitis C drugs in China, but this legacy business is not the point of the company today: most of the value investors are pricing in depends on drug candidates still in clinical trials that generate no revenue at all. Until a metabolic-disease drug such as ASC30 or ASC41 is approved and launched, Ascletis is funded mainly by capital raised from investors rather than by product sales.
Os argumentos a favor
Buyers argue that early obesity data — a Phase 2 US study reported 7.7% weight loss for its oral GLP-1 candidate — puts Ascletis in one of the most closely watched drug categories in the industry, and that its established, revenue-generating hepatitis C franchise shows the company can already get drugs through Chinese regulators and to market.
Os argumentos contra
Sellers worry that Ascletis' actual product revenue is still minimal, that its valuation rests almost entirely on obesity and metabolic-disease candidates years away from approval in a field crowded with better-funded rivals, and that its pivot away from the older hepatitis C business leaves little near-term commercial base to fall back on.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 23 de agosto de 2026 with claude-opus-5 — shared with all users
Viking's oral VK2735 tablet targets the same obesity patients with the same oral-pill format, making it the other emerging-biotech contender competing with ASC30 for prescriptions and for a partner or acquirer.
Lilly's orforglipron is the oral small molecule GLP-1 that Ascletis explicitly benchmarks ASC30 against on weight loss and tolerability, and its amylin agonist eloralintide competes head-on with Ascletis' ASC39.
Novo Nordisk defends the obesity market Ascletis is trying to enter, with oral semaglutide and the oral candidate amycretin aimed at exactly the same overweight and type 2 diabetes patients.
Both are clinical-stage biotechs whose entire value rests on a once-daily oral small molecule GLP-1 agonist for chronic weight management, with Structure's aleniglipron and Ascletis' ASC30 running competing global Phase III obesity programmes.
Hengrui's HRS-7535 is the Chinese oral small molecule GLP-1 furthest ahead in obesity and type 2 diabetes, competing with ASC30 both for Chinese patients and for out-licensing deals with Western partners.
Innovent's mazdutide is already the reference weight-loss therapy in China and is the incumbent ASC30 would have to displace in Ascletis' home market.
Balanço & Liquidez
Receita
$2M
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Resultado Líquido
$-387M
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Fluxo de Caixa Livre
$-300M
Capital Próprio Total
$2.39B
Passivo Total
$5M
Rácio de Liquidez
15.05
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$23.97
Preço Atual
$9.88
Margem de Segurança
+58.8%
Intervalo de Valor Justo
$22.77 - $25.17
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-18.5%
Rácio P/B
4.93
P/FCF
-
Margem Bruta
26.0%
ROIC
-20.8%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-20.8%
WACC
8.0%
ROIC − WACC
-28.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (5)
- Price CAGR 5.62%
- Debt/Equity ratio
- Current Ratio
- Analyst Consensus 78% Buy
- Net Margin Trend -17745.6% vs -23455.7%
Reprovado (9)
- ROIC -20.8%
- Gross Margin 26.0%
- P/B Ratio 4.93
- Operating Margin -17712.5%
- Positive Free Cash Flow
- DCF valuation (Unknown)
- ROE -18.9%
- Revenue Growth 5Y -43.4%
- Piotroski F-Score 0/9
Indisponível (13)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Jinzi Wu Ph.D. | Founder, Chairman & CEO | 62 |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director | 51 |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | 57 |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | 74 |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer | 65 |
| Mr. Ming Fai Chung CPA | Company Secretary | 46 |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for ASCLF, sourced from Markets Gazette.